Second Circular and Provisional Conference Programme
The Second International Conference on
Modern Vaccines Adjuvants & Delivery Systems
MVADS 2006 – 12-14 September 2006, The Royal Society of Medicine, London, UK
The drive for the new generation of vaccine therapies has precipitated a concurrent need for new and improved adjuvantation/delivery systems for these new vaccines. This new international conference will focus on updating the community on new adjuvant/delivery systems/technologies associated with developing modern vaccines strategies and vaccine research. There is now an urgent need for the development of these potent and safe adjuvants and delivery systems and MVADS 2006 will offer researchers a fresh forum to discuss this important topic in detail. MVADS 2006 is the follow up meeting to the successful MVADS 2003 conference held in Dublin in June 2003.
Modern vaccines are poorly immunogenic and need to be coupled with adjuvants/immunopotentiators to improve their effectiveness. There is also now a general realization that delivery of an antigen is critical to the success of a vaccine and that this whole topic has been, until recently, a neglected component of vaccinology with most of the emphasis being placed on antigen engineering. Now things have changed: there are a number of delivery systems that can potentiate and modulate, quantitatively and qualitatively, immune responses. MVADS 2006 offers an opportunity to discuss the different vaccine adjuvant/delivery systems available, their relative advantages and disadvantages and results obtained thus far and where new developments are beginning to appear.
MVADS 2006 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups.
Advisory Scientific Panel
John Morrow (InBios Inc., Seattle, USA)
Kingston Mills (Trinity College, Dublin, Ireland)
Derek O’Hagan (Chiron Corporation, Emeryville, USA)
John Samuel (University of Alberta, Canada)
Dorothea Sesardic (NIBSC, Potters Bar, UK)
Russell Mumper (University of Kentucky, Lexington, USA)
Bruce Weniger (CDC, Atlanta, USA)
Virgil Schijns (Intervet International, The Netherlands)
Jeff Powell (VaxInnate, USA)
Martin Pearse (CSL Ltd, Australia)
Gwyn Davies (OM Pharma, Switzerland)
John Clements (Tulane University, USA)
Jean-Francois Viret (Berna Biotech, Berne, Switzerland)
Alex von Gabain (Intercell AG, Vienna, Austria)
Geert van den Bossche (GSK Biologicals, Rixensart, Belgium)
Closing date for poster abstract submissions Friday 25th August 2006
Platinum Sponsor
Sponsored by
